RioFast (RioFast)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceMagaldratMagaldrat
Similar drugsTo uncover
  • RioFast
    suspension inwards 
    Takeda GmbH     Germany
  • RioFast
    pills inwards 
    Takeda GmbH     Germany
    • Dosage form: & nbspsuspension for oral administration.
    Composition:

    10 ml of a suspension of 800 mg / 10 ml (1 sachet) contain:

    Active ingredient: mg 800 mg (as a 10% suspension containing water 6819 - 7621 mg and sodium hypochlorite 0.42 mg);

    Excipients: Acacia gum - 150.0 mg, hypromellose - 4 thousand - 30.0 mg, maltol - 10.0 mg, sodium cyclamate - 20.0 mg, simethicone emulsion 30 % (simethicone 36.60 mg, methyl cellulose 3.05 mg, sorbic acid 0.12 mg, water 82.23 mg) 122.0 mg, silver sulfate 0.145 mg, chlorhexidine bigluconate solution 20% - 2.0 mg, cream flavor 225082 - 10.0 mg, caramel flavoring 217358 - 10.0 mg, - water 1725-2527 mg.

    10 ml of a suspension of 1600 mg / 10 ml (1 sachet) contain:

    Active ingredient: Magadrate 1600 mg (as a 20% suspension containing water 5357 - 6821 mg and sodium hypochlorite 0.51 mg);

    Excipients: acacia gum - 604,0 mg, hypromellose-15 - 101.6 mg, maltol - 10.0 mg, sodium cyclamate 20.0 mg, simethicone emulsion 30% (simethicone 30.48 mg, methylcellulose 2.54 mg, sorbic acid 0.10 mg, water 68.48 mg) 101.6 mg, silver sulfate 0.145 mg, solution of chlorhexidine bigluconate 20% - 2.0 mg, cream flavor 225082 - 15.0 mg, caramel flavoring 217358 - 15.0 mg, water - 1710-3174 mg.

    Description:

    RioFast, suspension for ingestion 800 mg / 10 ml: from white to light brown suspension with a caramel flavor.

    RioFast,suspension for ingestion 1600 mg / 10 ml: from white to light brown suspension with a caramel flavor.

    Pharmacotherapeutic group:Antacid agent
    ATX: & nbsp

    A.02.A.D.02   Magaldrat

    Pharmacodynamics:

    The mechanism of action of the magic is based on the instant regulation of the acidity of the gastric juice. RioFast has an antacid effect, which depends on the dose and pH: reduces the amount of acid and simultaneously binds pepsin, bile acids and lysolecithin, thus reducing the corrosive effect of gastric juice.

    Magadrat is a stable substance with a certain lattice-layered crystal structure and contains aluminum and magnesium hydroxides in one molecule. The antacid effect is due to the neutralization of protons by sulfate and hydroxide ions located at the nodes of the lattice structure. After neutralization, the lattice structure of the magdalite is destroyed.

    Magadrat does not affect gastric motility. Due to the fact that the drug maintains the pH in a therapeutically optimal range (pH 3 - 5) for 20 to 40 minutes, it does not cause an acid ricochet. The drug does not contain sugar and contains a low amount of sodium.

    800 mg of anhydrous magdalite neutralizes 18-25 mEq of hydrochloric acid.
    Pharmacokinetics:

    Magadrat is not absorbed in the gastrointestinal tract (GIT). During deacidification released small amounts of magnesium and aluminum ions which during the passage through the intestine are converted into soluble phosphates, and then output intestine. Some of the ions are suctioned. There was an increase in the level of aluminum ions in the blood plasma even in patients with normal renal function. Long-term use of preparations containing aluminum can cause a decrease in phosphate absorption.

    Indications:

    - heartburn;

    - acid diseases of the gastrointestinal tract (erosive gastroduodenitis, gastro- and duodenopatii caused by nonsteroidal anti-inflammatory drugs, stress ulcer, Zollinger - Ellison syndrome, gastroesophageal reflux disease);

    - symptomatic therapy of peptic ulcer of stomach and duodenum.

    Contraindications:

    - hypersensitivity to the components of the drug;

    - children under 12 years.

    Carefully:During the period of breastfeeding.
    Pregnancy and lactation:

    During pregnancy, the drug should be administered only for a short time to avoid the penetration of aluminum ions into the fetal tissues. During breastfeeding, the drug should be taken with caution because of the possible isolation of aluminum ions in breast milk. However, due to the low absorption of the drug, the negative impact on the baby is not proven.

    Dosing and Administration:

    Before use, the suspension must be homogenized, carefully stretching the sachet between the fingers. The contents of the sachet are swallowed in undiluted form or after dilution with water.

    The drug is taken 1 hour after eating and immediately before bedtime, 1 to 2 bags (suspension 800 mg / 10 ml) or 1 packet (suspension 1600 mg / 10 ml) for a short time for symptomatic therapy.

    The maximum daily intake for adults and children from 12 years: 6400 mg of magalhydrate per day (8 bags of a suspension of 800 mg / 10 ml or 4 bags of a suspension of 1600 mg / 10 ml).

    If the symptoms do not disappear for more than 2 weeks during drug therapy, a clinical examination of the patient should be performed to exclude the presence of a malignant disease.

    In elderly patients, dose adjustment is not required.

    Side effects:

    To classify the frequency of unwanted effects, the following categories are used: Very frequent (> 10%), Frequent (> 1 % - <10%), Infrequent (> 0.1% - <1%), Rare (> 0.01% - <0.1%), Very rare, including individual reports (<0.01%).

    From the digestive system:

    Frequent: unformed stool;

    Very rare: diarrhea.

    Due to prolonged use in high doses, as well as in patients with renal insufficiency, the drug can cause an increase in the concentration of aluminum and magnesium ions in the blood, which can lead to the deposition of aluminum, mainly in the nervous and bone tissues, and also to a decrease in the phosphate content in bone tissue.

    Overdose:

    There were no cases of overdose. Due to the fact that the active ingredient does not dissolve at pH values ​​above 5, drug intoxication due to overdose is unlikely.

    Interaction:

    Due to the fact that antacids can reduce the absorption of other drugs in a joint application, the interval between the taking of the drug Riofast and other drugs should be at least 2 hours.

    Taking antacids can significantly reduce the absorption of antibiotics. As a result, antacids are not recommended for antibiotic therapy.

    With simultaneous use with digoxin, isoniazid, iron compounds and chlorpromazine, RioFast can cause a slight decrease in absorption of these drugs.

    RioFast can potentiate the anticoagulant effect of coumarin derivatives.

    The drug should not be taken with beverages that have acid properties (for example, fruit juices, wine), as well as with effervescent tablets containing citric or tartaric acid, due to increased intestinal absorption of aluminum ions.

    Special instructions:

    Due to the possible relationship between elevated plasma concentrations of aluminum and the development of encephalopathy, special attention should be paid to patients on dialysis.

    In patients with impaired renal function (creatinine clearance less than 30 ml / min), the RioFast should be taken with constant monitoring of the content of aluminum and magnesium ions in the blood plasma. The concentration of aluminum ions in the blood plasma should not exceed 40 ng / ml.

    In the case of permanent or often recurring disorders, it is necessary to establish the cause of relapse, that is, the presence of the underlying disease.

    In patients with peptic ulcer or duodenal ulcer, it is necessary to test for the presence of Helicobacter pylori. If the test is positive, standard therapy for eradication should be performed Helicobacter pylori.

    The drug does not contain sugar and can be used in patients with diabetes mellitus.

    Form release / dosage:

    Suspension for oral administration of 800 mg / 10 ml and 1600 mg / 10 ml.

    Packaging:

    For 10 ml of the drug in a bag of polyester, aluminum and polyethylene with a sealing tape of polyethylene and polyester.

    For 10 or 20 bags together with the instructions for use are placed in a cardboard box.

    Storage conditions:

    At a temperature of 8-25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    The drug can not be used after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:PL-000787
    Date of registration:03.10.2011
    The owner of the registration certificate:Takeda GmbHTakeda GmbH Germany
    Manufacturer: & nbsp
    Representation: & nbspTAKEDA TAKEDA Japan
    Information update date: & nbsp09.01.2014
    Illustrated instructions
      Instructions
      Up